Responses
Ovarian Cancer
Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer: A Sankai Gynecology Cancer Study Group Study
Compose a Response to This Article
Other responses
No responses have been published for this article.